Investigational drugs targeting cardiac fibrosis

References

• Beltrami CA, Finato N, Rocco M et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89(1), 151–163 (1994).
   PubMed Web of Science ®Google Scholar
• Diez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 91(5), 1450–1456 (1995).
   Google Scholar
• Dostal DE. Regulation of cardiac collagen: Angiotensin and cross-talk with local growth factors. Hypertension 37(3), 841–844 (2001).
   Google Scholar
• Grossman W. Diastolic dysfunction and congestive heart failure. Circulation 81(2 Suppl.), III1–III7 (1990).
   Google Scholar
• Masci PG, Barison A, Aquaro GD et al. Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. Int. J. Cardiol. 157(1), 43–47 (2012).
   Google Scholar
• Marijianowski MM, Teeling P, Mann J, Becker AE. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J. Am. Coll. Cardiol. 25(6), 1263–1272 (1995).
   PubMed Web of Science ®Google Scholar
• Blauwet LA, Ackerman MJ, Edwards WD, Riehle DL, Ommen SR. Myocardial fibrosis in patients with symptomatic obstructive hypertrophic cardiomyopathy: correlation with echocardiographic measurements, sarcomeric genotypes, and pro-left ventricular hypertrophy polymorphisms involving the renin-angiotensin-aldosterone system. Cardiovasc. Pathol. 18(5), 262–268 (2009).
   Google Scholar
• Factor SM, Butany J, Sole MJ, Wigle ED, Williams WC, Rojkind M. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 17(6), 1343–1351 (1991).
   Google Scholar
• Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ. Res. 64(6), 1041–1050 (1989).
   PubMed Web of Science ®Google Scholar
• Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102(12), 1388–1393 (2000).
   PubMed Web of Science ®Google Scholar
• Tan AY, Zimetbaum P. Atrial fibrillation and atrial fibrosis. J. Cardiovasc. Pharmacol. 57(6), 625–629 (2011).
   Google Scholar
• Zeisberg EM, Tarnavski O, Zeisberg M et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13(8), 952–961 (2007).
   PubMed Web of Science ®Google Scholar
• Edgley AJ, Krum H, Kelly DJ. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-beta. Cardiovasc. Ther. 30(1), e30–40 (2012).
   Google Scholar
• Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3(5), 349–363 (2002).
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ et al. Recent developments in myofibroblast biology: Paradigms for connective tissue remodeling. Am. J. Pathol. 180(4), 1340–1355 (2012).
   PubMed Web of Science ®Google Scholar
• Barker TH, Baneyx G, Cardo-Vila M et al. Sparc regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J. Biol. Chem. 280(43), 36483–36493 (2005).
   Google Scholar
• Horiguchi M, Ota M, Rifkin DB. Matrix control of transforming growth factor-beta function. J. Biochem. 152(4), 321–329 (2012).
   PubMed Web of Science ®Google Scholar
• Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat. Rev. Cardiol. 10(1), 15–26 (2013).
   PubMed Web of Science ®Google Scholar
• Wei H, Bedja D, Koitabashi N et al. Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of tgf-beta signaling. Proc. Natl Acad. Sci. USA 109(14), E841–850 (2012).
   PubMed Web of Science ®Google Scholar
• Kazakov A, Hall R, Jagoda P et al. Inhibition of endothelial nitric oxide synthase induces and enhances myocardial fibrosis. Cardiovasc. Res. doi:10.1093/cvr/cvt181 (2013) (Epub ahead of print).
   Google Scholar
• Kanellakis P, Pomilio G, Agrotis A et al. Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor. Br. J. Pharmacol. 160(8), 2085–2096 (2010).
   PubMed Web of Science ®Google Scholar
• Sun Y, Carretero OA, Xu J et al. Deletion of inducible nitric oxide synthase provides cardioprotection in mice with 2-kidney, 1-clip hypertension. Hypertension 53(1), 49–56 (2009).
   Google Scholar
• Wang Y, Wu Y, Chen J, Zhao S, Li H. Pirfenidone attenuates cardiac fibrosis in a mouse model of tac-induced left ventricular remodeling by suppressing nlrp3 inflammasome formation. Cardiology 126(1), 1–11 (2013).
   PubMed Web of Science ®Google Scholar
• Muller-Brunotte R, Kahan T, Lopez B et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: Results from the swedish irbesartan left ventricular hypertrophy investigation versus atenolol (silvhia). J. Hypertens. 25(9), 1958–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Laviades C, Varo N, Fernandez J et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98(6), 535–540 (1998).
   PubMed Web of Science ®Google Scholar
• Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83(6), 1849–1865 (1991).
   PubMed Web of Science ®Google Scholar
• Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin. Chem. 39(4), 635–640 (1993).
   PubMed Web of Science ®Google Scholar
• Segura AM, Frazier OH, Buja LM. Fibrosis and heart failure. Heart Fail. Rev. doi:10.1007/s10741-012-9365-4 (2012) (Epub ahead of print).
   Google Scholar
• Friedrich MG, Abdel-Aty H, Taylor A, Schulz-Menger J, Messroghli D, Dietz R. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 51(16), 1581–1587 (2008).
   Google Scholar
• Vermes E, Carbone I, Friedrich MG, Merchant N. Patterns of myocardial late enhancement: typical and atypical features. Arch. Cardiovasc. Dis. 105(5), 300–308 (2012).
   Google Scholar
• Gahide G, Bertrand D, Roubille F et al. Mr delayed enhancement imaging findings in suspected acute myocarditis. Eur. Radiol. 20(1), 65–72 (2010).
   Google Scholar
• Machado S, Roubille F, Gahide G et al. Can troponin elevation predict worse prognosis in patients with acute pericarditis? Ann. Cardiol. Angeiol. (Paris) 59(1), 1–7 (2010).
   Google Scholar
• Messroghli DR, Niendorf T, Schulz-Menger J, Dietz R, Friedrich MG. T1 mapping in patients with acute myocardial infarction. J. Cardiovasc. Magn. Reson. 5(2), 353–359 (2003).
   PubMed Web of Science ®Google Scholar
• Messroghli DR, Walters K, Plein S et al. Myocardial T1 mapping: Application to patients with acute and chronic myocardial infarction. Magn. Reson. Med. 58(1), 34–40 (2007).
   PubMed Web of Science ®Google Scholar
• Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 57(8), 891–903 (2011).
   PubMed Web of Science ®Google Scholar
• Iles L, Pfluger H, Phrommintikul A et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J. Am. Coll. Cardiol. 52(19), 1574–1580 (2008).
   PubMed Web of Science ®Google Scholar
• Robbers LF, Baars EN, Brouwer WP et al. T1 mapping shows increased extracellular matrix size in the myocardium due to amyloid depositions. Circ. Cardiovasc. Imaging 5(3), 423–426 (2012).
   Google Scholar
• Jerosch-Herold M, Sheridan DC, Kushner JD et al. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 295(3), H1234–H1242 (2008).
   Google Scholar
• Ugander M, Oki AJ, Hsu LY et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur. Heart J. 33(10), 1268–1278 (2012).
   PubMed Web of Science ®Google Scholar
• Wong TC, Piehler K, Meier CG et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 126(10), 1206–1216 (2012).
   PubMed Web of Science ®Google Scholar
• Liu S, Han J, Nacif MS et al. Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials. J. Cardiovasc. Magn. Reson. 14, 90 (2012).
   Google Scholar
• Ferreira VM, Piechnik SK, Dall'Armellina E et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 14, 42 (2012).
   Google Scholar
• Kolipaka A, McGee KP, Araoz PA et al. Mr elastography as a method for the assessment of myocardial stiffness: Comparison with an established pressure-volume model in a left ventricular model of the heart. Magn. Reson. Med. 62(1), 135–140 (2009).
   Google Scholar
• Robert B, Sinkus R, Gennisson JL, Fink M. Application of dense-mr-elastography to the human heart. Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine Society of Magnetic Resonance in Medicine (2009) 62(5):1155–1163.
   Google Scholar
• Sack I, Rump J, Elgeti T, Samani A, Braun J. Mr elastography of the human heart: Noninvasive assessment of myocardial elasticity changes by shear wave amplitude variations. Magn. Reson. Med. 61(3), 668–677 (2009).
   Google Scholar
• De Smet K, Verdries D, Tanaka K, De Mey J, De Maeseneer M. MRI in the assessment of non ischemic myocardial diseases. Eur. J. Radiol. 81(7), 1546–1548 (2012).
   Google Scholar
• Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 126(10), 1286–1300 (2012).
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Sechtem U, Schulz-Menger J et al. Cardiovascular magnetic resonance in myocarditis: A JACC white paper. J. Am. Coll. Cardiol. 53(17), 1475–1487 (2009).
   PubMed Web of Science ®Google Scholar
• Schulz-Menger J, Wassmuth R, Abdel-Aty H et al. Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance. Heart 92(3), 399–400 (2006).
   PubMedGoogle Scholar
• Won S, Davies-Venn C, Liu S, Bluemke DA. Noninvasive imaging of myocardial extracellular matrix for assessment of fibrosis. Curr. Opin. Cardiol. 28(3), 282–289 (2013).
   Google Scholar
• Brilla CG. Regression of myocardial fibrosis in hypertensive heart disease: Diverse effects of various antihypertensive drugs. Cardiovasc. Res. 46(2), 324–331 (2000).
   Google Scholar
• Lopez B, Querejeta R, Varo N et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 104(3), 286–291 (2001).
   PubMed Web of Science ®Google Scholar
• Iwata M, Cowling RT, Yeo SJ, Greenberg B. Targeting the ace2-ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J.Mol. Cell. Cardiol. 51(4), 542–547 (2011).
   Google Scholar
• Gavras I, Gavras H. Angiotensin II as a cardiovascular risk factor. J. Hum. hypertens. 16(Suppl. 2), S2–6 (2002).
   Google Scholar
• Iwata M, Cowling RT, Gurantz D et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am. J. Physiol. Heart Circ. Physiol. 289(6), H2356–2363 (2005).
   Google Scholar
• Duerrschmid C, Crawford JR, Reineke E et al. TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis. J. Mol. Cell. Cardiol. 57, 59–67 (2013).
   PubMed Web of Science ®Google Scholar
• Nakagami F, Koriyama H, Nakagami H et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PLoS ONE 8(3), e60493 (2013).
   Google Scholar
• Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 28(2), 269–275 (1996).
   PubMed Web of Science ®Google Scholar
• Schieffer B, Wirger A, Meybrunn M et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89(5), 2273–2282 (1994).
   PubMed Web of Science ®Google Scholar
• Matsusaka H, Kinugawa S, Ide T et al. Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction. J. Cardiovasc. Pharmacol. 48(3), 95–102 (2006).
   PubMed Web of Science ®Google Scholar
• Kawamura M, Ito H, Onuki T et al. Candesartan decreases type III procollagen-n-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation. J. Cardiovasc. Pharmacol. 55(5), 511–517 (2010).
   Google Scholar
• Rabelo LA, Alenina N, Bader M. Ace2-angiotensin-(1-7)-mas axis and oxidative stress in cardiovascular disease. Hypertens. Res. 34(2), 154–160 (2011).
   Google Scholar
• Keidar S, Kaplan M, Gamliel-Lazarovich A. Ace2 of the heart: From angiotensin i to angiotensin (1-7). Cardiovasc. Res. 73(3), 463–469 (2007).
   PubMed Web of Science ®Google Scholar
• Takeda Y, Zhu A, Yoneda T, Usukura M, Takata H, Yamagishi M. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in dahl salt-sensitive hypertensive rats. Am. J. Hypertens. 20(10), 1119–1124 (2007).
   Google Scholar
• Trask AJ, Groban L, Westwood BM et al. Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in ren-2 hypertensive rats. Am. J. Hypertens. 23(6), 687–693 (2010).
   Google Scholar
• Dong B, Yu QT, Dai HY et al. Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 59(8), 739–747 (2012).
   Google Scholar
• Azibani F, Benard L, Schlossarek S et al. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart. Hypertension 59(6), 1179–1187 (2012).
   PubMed Web of Science ®Google Scholar
• Azibani F, Devaux Y, Coutance G et al. Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. PloS ONE 7(5), e38197 (2012).
   Google Scholar
• Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on lv function, structure, and fibrosis markers in metabolic syndrome. JACC Cardiovasc. Imaging 4(12), 1239–1249 (2011).
   PubMed Web of Science ®Google Scholar
• Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, Marwick TH. Fibrosis and cardiac function in obesity: A randomised controlled trial of aldosterone blockade. Heart 99(5), 320–326 (2013).
   PubMed Web of Science ®Google Scholar
• Mak GJ, Ledwidge MT, Watson CJ et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J. Am. Coll. Cardiol. 54(18), 1674–1682 (2009).
   Google Scholar
• Roubille F, Tardif JC. New therapeutic targets in cardiology: Heart failure and arrhythmia: HCN channels. Circulation 127(19), 1986–1996 (2013).
   Google Scholar
• Busseuil D, Shi Y, Mecteau M et al. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology 117(3), 234–242 (2010).
   Google Scholar
• Becher PM, Lindner D, Miteva K et al. Role of heart rate reduction in the prevention of experimental heart failure: Comparison between If-channel blockade and beta-receptor blockade. Hypertension 59(5), 949–957 (2012).
   PubMed Web of Science ®Google Scholar
• Khoueiry Z, Roubille C, Nagot N et al. Could heart rate play a role in pericardial inflammation? Med. Hypotheses 79(4), 512–515 (2012).
   Google Scholar
• Li YC, Luo Q, Ge LS et al. Ivabradine inhibits the production of proinflammatory cytokines and inducible nitric oxide synthase in acute coxsackievirus B3-induced myocarditis. Biochem. Biophys. Res. Commun. 431(3), 450–455 (2013).
   Google Scholar
• Ieki K, Yazaki Y, Yamaoki K et al. Effect of long-term treatment with beta-blocker on cardiac hypertrophy in shr. J. Mol. Cell. Cardiol. 21(Suppl. 5), 113–119 (1989).
   Google Scholar
• Liao Y, Asakura M, Takashima S et al. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 110(6), 692–699 (2004).
   Google Scholar
• Bartholomeu JB, Vanzelli AS, Rolim NP et al. Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure. J. Mol. Cell. Cardiol. 45(2), 240–249 (2008).
   Google Scholar
• Novoyatleva T, Schymura Y, Janssen W et al. Deletion of fn14 receptor protects from right heart fibrosis and dysfunction. Basic Res. Cardiol. 108(2), 325 (2013).
   Google Scholar
• Zhang W, Chancey AL, Tzeng HP et al. The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation 124(19), 2106–2116 (2011).
   Google Scholar
• Hamid T, Gu Y, Ortines RV et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappab and inflammatory activation. Circulation 119(10), 1386–1397 (2009).
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117(6), 1538–1549 (2007).
   PubMed Web of Science ®Google Scholar
• Januzzi JLJr. ST2 as a cardiovascular risk biomarker: From the bench to the bedside. J. Cardiovasc. Transl. Res. 6(4), 493–500 (2013).
   PubMed Web of Science ®Google Scholar
• Honsho S, Nishikawa S, Amano K et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ. Res. 105(11), 1149–1158 (2009).
   PubMed Web of Science ®Google Scholar
• Szardien S, Nef HM, Voss S et al. Regression of cardiac hypertrophy by granulocyte colony-stimulating factor-stimulated interleukin-1beta synthesis. Eur. Heart J. 33(5), 595–605 (2012).
   Google Scholar
• Bujak M, Dobaczewski M, Chatila K et al. Interleukin-1 receptor Type I signaling critically regulates infarct healing and cardiac remodeling. Am. J. Pathol. 173(1), 57–67 (2008).
   PubMed Web of Science ®Google Scholar
• Obana M, Maeda M, Takeda K et al. Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation 121(5), 684–691 (2010).
   PubMed Web of Science ®Google Scholar
• Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56(2), 225–231 (2010).
   PubMed Web of Science ®Google Scholar
• de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr. Heart Fail. Rep. 7(1), 1–8 (2010).
   PubMedGoogle Scholar
• Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110(19), 3121–3128 (2004).
   PubMed Web of Science ®Google Scholar
• Roubille F, Prunier F, Barrere-Lemaire S et al. What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials. Cardiovasc. Drugs Ther. 27(4), 315–331 (2013).
   PubMed Web of Science ®Google Scholar
• Briest W, Homagk L, Baba HA et al. Cardiac remodeling in erythropoietin-transgenic mice. Cell. Physiol. Biochem. 14(4–6), 277–284 (2004).
   Google Scholar
• Oie E, Bjornerheim R, Clausen OP, Attramadal H. Cyclosporin a inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am. J. Physiol. Heart Circ. Physiol. 278(6), H2115–2123 (2000).
   PubMed Web of Science ®Google Scholar
• Yang G, Meguro T, Hong C et al. Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis. J. Mol. Cell. Cardiol. 33(8), 1505–1514 (2001).
   Google Scholar
• Takeda Y, Yoneda T, Demura M, Usukura M, Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 105(6), 677–679 (2002).
   Google Scholar
• Shahbaz AU, Kamalov G, Zhao W et al. Mitochondria-targeted cardioprotection in aldosteronism. J. Cardiovasc. Pharmacol. 57(1), 37–43 (2011).
   Google Scholar
• Dai DF, Chen T, Szeto H et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J. Am. Coll. Cardiol. 58(1), 73–82 (2011).
   PubMed Web of Science ®Google Scholar
• Wang ZF, Wang NP, Harmouche S et al. Postconditioning promotes the cardiac repair through balancing collagen degradation and synthesis after myocardial infarction in rats. Basic Res. Cardiol. 108(1), 318 (2013).
   Google Scholar
• Nagayama T, Hsu S, Zhang M et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J. Am. Coll. Cardiol. 53(2), 207–215 (2009).
   PubMed Web of Science ®Google Scholar
• Westermann D, Becher PM, Lindner D et al. Selective PDE5A II inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin ii-induced heart failure in vivo. Basic Res. Cardiol. 107(6), 308 (2012).
   PubMed Web of Science ®Google Scholar
• Wang JS, Kovanecz I, Vernet D et al. Effects of sildenafil and/or muscle derived stem cells on myocardial infarction. J. Transl. Med. 10, 159 (2012).
   Google Scholar
• Kim KH, Kim YJ, Ohn JH et al. Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: Benefits of ventricular remodeling and exercise capacity. Circulation 125(11), 1390–1401 (2012).
   Google Scholar
• Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA. Cardiac uses of phosphodiesterase-5 inhibitors. J. Am. Coll. Cardiol. 59(1), 9–15 (2012).
   PubMed Web of Science ®Google Scholar
• Giannetta E, Isidori AM, Galea N et al. Chronic inhibition of CGMP phosphodiesterase 5a improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 125(19), 2323–2333 (2012).
   PubMed Web of Science ®Google Scholar
• Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-b pathway. J. Am. Coll. Cardiol. 43(8), 1481–1488 (2004).
   Google Scholar
• Elnakish MT, Kuppusamy P, Khan M. Stem cell transplantation as a therapy for cardiac fibrosis. J. Pathol. 229(2), 347–354 (2013).
   Google Scholar
• Uchinaka A, Kawaguchi N, Hamada Y et al. Transplantation of myoblast sheets that secrete the novel peptide SVVYGLR improves cardiac function in failing hearts. Cardiovasc. Res. 99(1), 102–110 (2013).
   Google Scholar
• Thum T, Lorenzen JM. Cardiac fibrosis revisited by microrna therapeutics. Circulation 126(7), 800–802 (2012).
   Google Scholar
• Bauersachs J. Regulation of myocardial fibrosis by micrornas. J. Cardiovasc. Pharmacol. 56(5), 454–459 (2010).
   Google Scholar
• Pan Z, Sun X, Shan H et al. Microrna-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the fbj osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 126(7), 840–850 (2012).
   PubMed Web of Science ®Google Scholar
• Aurora AB, Mahmoud AI, Luo X et al. Microrna-214 protects the mouse heart from ischemic injury by controlling ca(2)(+) overload and cell death. J. Clin. Invest. 122(4), 1222–1232 (2012).
   PubMed Web of Science ®Google Scholar
• Topkara VK, Mann DL. Role of micrornas in cardiac remodeling and heart failure. Cardiovasc. Drugs Ther. 25(2), 171–182 (2011).
   PubMed Web of Science ®Google Scholar
• Bauersachs J. Mir-21: a central regulator of fibrosis not only in the broken heart. Cardiovasc. Res. 96(2), 227–229, discussion 230–223 (2012).
   Google Scholar
• Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH, Thum T. Transforming growth factor-beta-induced endothelial-to-mesenchymal transition is partly mediated by microrna-21. Arterioscler. Thromb. Vasc. Biol. 32(2), 361–369 (2012).
   PubMed Web of Science ®Google Scholar
• van Rooij E, Marshall WS, Olson EN. Toward microrna-based therapeutics for heart disease: The sense in antisense. Circ. Res. 103(9), 919–928 (2008).
   Web of Science ®Google Scholar
• van Rooij E, Olson EN: Searching for mir-acles in cardiac fibrosis. Circ. Res. 104(2), 138–140 (2009).
   Google Scholar
• Thum T, Gross C, Fiedler J et al. Microrna-21 contributes to myocardial disease by stimulating map kinase signalling in fibroblasts. Nature 456(7224), 980–984 (2008).
   PubMed Web of Science ®Google Scholar
• van Rooij E, Sutherland LB, Thatcher JE et al. Dysregulation of micrornas after myocardial infarction reveals a role of mir-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA 105(35), 13027–13032 (2008).
   PubMed Web of Science ®Google Scholar
• Bernardo BC, Gao XM, Winbanks CE et al. Therapeutic inhibition of the mir-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl Acad. Sci. USA 109(43), 17615–17620 (2012).
   PubMed Web of Science ®Google Scholar
• Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10(5), 927–939 (2005).
   Google Scholar
• Bujak M, Frangogiannis NG. The role of tgf-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 74(2), 184–195 (2007).
   PubMed Web of Science ®Google Scholar
• Gieling RG, Burt AD, Mann DA. Fibrosis and cirrhosis reversibility - molecular mechanisms. Clin. Liver Dis. 12(4), 915–937, xi (2008).
   Google Scholar
• Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent smad pathways: the role of smad3. Hypertension 54(4), 877–884 (2009).
   PubMed Web of Science ®Google Scholar
• Flanders KC. Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 85(2), 47–64 (2004).
   PubMed Web of Science ®Google Scholar
• Xavier S, Piek E, Fujii M et al. Amelioration of radiation-induced fibrosis: Inhibition of transforming growth factor-beta signaling by halofuginone. J. Biol. Chem. 279(15), 15167–15176 (2004).
   PubMed Web of Science ®Google Scholar
• Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 19(1), 1–11 (2005).
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 114(9), 1308–1316 (2004).
   PubMed Web of Science ®Google Scholar
• Araujo-Jorge TC, Waghabi MC, Bailly S, Feige JJ. The TGF-beta pathway as an emerging target for chagas disease therapy. Clin. Pharmacol. Ther. 92(5), 613–621 (2012).
   Google Scholar
• Jiang B, Li D, Deng Y et al. Salvianolic acid a, a novel matrix metalloproteinase-9 inhibitor, prevents cardiac remodeling in spontaneously hypertensive rats. PLoS ONE 8(3), e59621 (2013).
   Google Scholar
• Chiao YA, Ramirez TA, Zamilpa R et al. Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc. Res. 96(3), 444–455 (2012).
   Web of Science ®Google Scholar
• Georgescu SP, Aronovitz MJ, Iovanna JL, Patten RD, Kyriakis JM, Goruppi S: Decreased metalloprotease 9 induction, cardiac fibrosis, and higher autophagy after pressure overload in mice lacking the transcriptional regulator p8. Am. J. Physiol. Cell Physiol. 301(5), C1046–C1056 (2011).
   Google Scholar
• Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J. Pharmacol. Exp. Ther. 339(1), 143–151 (2011).
   PubMed Web of Science ®Google Scholar